In re Application of:

Wolfgang HEIL et al.

Confirmation No.: 7991

Serial No.: 09/757,688

Examiner:

L.S. Channavajjala

Filed:

January 11, 2001

Group Art Unit:

1615

Title:

DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

MAIL STOP FEE AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

TIMING AND FEES

| \boxtimes | Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: | | | | | | | |
|-------------|---|---|--|--|--|--|--|--|
| | | within three months of the filing date of a national application other than a CPA under § 1.53(d); | | | | | | |
| | | within three months of the actual filing date of the national phase of a PCT application; OR | | | | | | |
| | \boxtimes | before the mailing of a first substantive office action (including after filing of an RCE). | | | | | | |
| | | 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the specified in 37 C.F.R. § 1.97(b), but before the mailing date of: | | | | | | |
| | | a final rejection under 37 C.F.R. § 1.113; | | | | | | |
| | | termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR | | | | | | |
| | | a notice of allowance under 37 C.F.R. § 1.311; and | | | | | | |
| | is acco | ompanied by: | | | | | | |
| | | | | | | | | |

| | the statement as specified in 37 C.F.R. § 1.97(e) set out below; OI | 3 | | | | | | |
|-------------|--|---------|--|--|--|--|--|--|
| | a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p). | | | | | | | |
| | Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after mailing date of the following actions which have not been withdrawn: | er the | | | | | | |
| | a final action under 37 C.F.R. § 1.113; | | | | | | | |
| | termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); O | R | | | | | | |
| | a notice of allowance under 37 C.F.R. § 1.311; | | | | | | | |
| | AND is filed on or before payment of the issue fee; AND is accompanied by: | | | | | | | |
| | the statement as specified in 37 C.F.R. § 1.97(e) as set forth below the fee of \$180.00 under 37 C.F.R. § 1.17(p). | v, and | | | | | | |
| STATE | EMENTS UNDER 37 C.F.R. 1.97(e) | | | | | | | |
| | Each item of information contained in this information disclosure statement was in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of information disclosure statement; or | cation | | | | | | |
| | No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement. | | | | | | | |
| CITED | MATERIALS | | | | | | | |
| | Copies of materials listed but not attached were cited in benefit (35 U.S.C. § ancestor application Serial No, on Form 892 by the Examiner and/or 1449 by the applicant; see 37 C.F.R. § 1.98(d). | | | | | | | |
| | Copies of materials listed but not attached were cited in an international search dated | report | | | | | | |
| \boxtimes | Copies of the materials listed are attached (except for the foregoing). | | | | | | | |
| Non-l | ENGLISH LANGUAGE REFERENCES | | | | | | | |
| | An English-language search report or equivalent paper from a foreign patent of provided indicating the relevance of the cited reference(s). | fice is | | | | | | |
| | A foreign-language search report from a foreign patent office is provided pertinent parts are translated substantively below: | , and | | | | | | |

X = document of particular relevance when it is taken alone

Y = document of particular relevance when it is combined with another such document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

Translation of other relevant information on foreign search report

OTHER INFORMATION

None

PAYMENT OF FEES DUE (IF ANY):

| A check for \$ | covering the fee identified above is | attached. |
|------------------|--------------------------------------|-------------------------------|
| Please charge to | Deposit Account No. 13-3402 \$ | for the fee identified above. |
| The Commission | anar is haraby authorized to shore | e or oradit only overnovment |

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account No. 13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

John A. Sopp Reg. No. 33,103

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400 2200 Clarendon Boulevard

Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: PLOVIN-2A

Date: March 31, 2005

JAS/slm:K:\plovin\2a\IDS & 1449.doc

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| U | Inder the Pap | erwork Re | duction A | ct of 1995, n | o persons are re | equired to respond to a collection of info | ormation unl | ess it contains | a valid OMB control num | ber. | |
|-------------------------------|-------------------------|---------------------|-----------|--------------------|---|--|------------------------------|--|---|----------------|--|
| Substitute for form 1449A/PTO | | | | | | Complete if Known | | | | | |
| | | | | | | Application Number | pplication Number 09/757,688 | | | | |
| INFC | RMA | FION | DIS | CLOS | URE | Filing Date | Janua | January 11, 2001 | | | |
| STATEMENT BY APPLICANT | | | | | | First Named Inventor | Wolfgang HEIL et al. | | | | |
| | | | | | | Group Art Unit | 1615 | | | | |
| | (use as n | nany she | eets as | necessar | y) | Examiner Name | L.S. C | Channavajjala | | | |
| Sheet | 1 | 1 | of | | 1 | Attorney Docket Number | PLOVIN-2A | | | | |
| | | | | | U.S. P | ATENT DOCUMENTS | | | | | |
| | U.S. Patent Document | | | | | | | | | | |
| Examiner Initials * | Cite No.1 | | Numbe | er | Kind Code ² (<i>if known</i>) | Name of Patentee or Applic of Cited Document | ant | Date of F | Date of Publication of Cited DocumentMM-DD-YYYY | | |
| | | | | | | · · · · · · · · · · · · · · · · · · · | | | | | |
| | · | | | | | | | | | | |
| | | | | | FOREIGI | N PATENT DOCUMENTS | | | | | |
| | Foreign Patent Document | | | | | Date of Publication of | | Pages, Columns, Lines, Where Relevant | ı | | |
| Examiner Initials* | Cite No.1 | Office ³ | Νι | ımber ⁴ | Kind Code ⁵ (<i>if known</i>) | Name of Patentee or Applicant of Cited Document | f Cited Document Passage | | Passages or Relevant Figures Appear | T ⁶ | |

| | | | | | | | |
|--|--|---|-------------|--|--|--|--|
| | | NON PATENT LITERATURE DOCUMENTS | | | | | |
| Examiner Initials * Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, maginitials * Cite No. journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where page (s). | | | | | | | |
| | | Y. Pramar et al. "Preformulation Studies of Spironolactone: Effect of pH, Two Buffer Species, Ionic Strength, and Temperature on Stability", Journal of Pharm. Sciences, Vol. 80, No. 6, (1991), pgs. 551-553 | | | | | |
| | | E. R. Garrett et al., "Prediction of Stability in Pharmaceutical Preparations XVI: Kinetics of Hydrolysis of Canrenone and Lactonization of Canrenoic Acid", Vol. 60, No. 12, (1971), pgs. 1801-1809 | | | | | |
| ···- | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Examiner Signature | | Date Considered | | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.